Medivir Aktiebolag (publ) held its annual general meeting today on
Approval of profit and loss accounts and balance sheets, and discharge from liability of the board members and the managing director
The annual general meeting resolved to approve the profit and loss accounts and balance sheets for the financial year 2023. The persons who had been board members and managing director were discharged from liability with respect to their respective management of the company for the financial year 2023.
Distribution of the company's profit or loss
The annual general meeting resolved, in accordance with the board's proposal, that the company's results should be carried forward.
Remuneration to the board of directors and the auditor
The annual general meeting resolved, in accordance with the nomination committee's proposal, that the remuneration to the board shall be paid in a total amount of not more than
Election of the board of directors and auditor
The annual general meeting resolved, in accordance with the nomination committee's proposal, that the number of board members shall be six ordinary members with no deputy board members and that the number of auditors shall be one with no deputies.
Further, the annual general meeting resolved, in accordance with the nomination committee's proposal, to re-elect
The annual general meeting resolved, in accordance with the nomination committee's proposal and the board of directors' recommendation, to re-elect
Guidelines for remuneration to senior executives
The annual general meeting resolved to adopt new guidelines for remuneration to senior executives, in accordance with the board's proposal.
The board of directors' remuneration report
The annual general meeting resolved to approve of the remuneration report submitted by the board of directors.
Authorisation to issue new shares
The annual general meeting further resolved, in accordance with the board's proposal, to authorize the board, up and until the next annual general meeting, on one or several occasions and with or without pre-emptive rights for shareholders, to resolve on the issue of new ordinary shares, comprising a total of not more than 20 per cent of the total number of outstanding shares in the company after the utilization of the authorization.
The purpose of the authorization is to provide the Board with flexibility in its work to ensure that the company can be provided with capital in an appropriate manner for the financing of operations. Issuance of new shares pursuant to the authorization shall be carried out on market term.
Long-term incentive program in the form of a share matching program (LTIP 2024)
Lastly, the annual general meeting resolved, in accordance with the board's proposal, to adopt a long-term incentive program in the form of a share matching program for key employees (LTIP 2024), including resolutions to authorize the board to increase the company's share capital by not more than
More information about the resolutions is available in the notice and the complete proposals included therein which are available on the company's website, www.medivir.com.
For additional information, please contact;
Telephone: +46 8 5468 3100
E-mail: magnus.christensen@medivir.com
About
https://news.cision.com/medivir/r/resolutions-at-the-annual-general-meeting-in-medivir-on-7-may-2024,c3975084
https://mb.cision.com/Main/652/3975084/2783748.pdf
(c) 2024 Cision. All rights reserved., source